Literature DB >> 35350712

A case of isolated unilateral renal mucormycosis post COVID-19 pneumonia with fatal outcome.

Rajiv Kumar Sethia1, Aakib Hamid Charag1.   

Abstract

Mucormycosis is a rare disease. It is typically seen in immunocompromised patients. Isolated renal mucormycosis is an extremely rare disease. We here report a case of isolated renal mucormycosis who had recently recovered from COVID-19 pneumonia. The patient was a known case of diabetes mellitus and had already developed acute kidney injury when he reported to us. Despite aggressive medical and surgical management, the patient succumbed to the disease.
© 2022 The Authors.

Entities:  

Keywords:  COVID-19; Emphysematous; Mucormycosis; Pyelonephritis

Year:  2022        PMID: 35350712      PMCID: PMC8948472          DOI: 10.1016/j.eucr.2022.102061

Source DB:  PubMed          Journal:  Urol Case Rep        ISSN: 2214-4420


Introduction

There has been an exponential increase in the rhinocerebral mucormycosis in India after second Covid-19 wave. Isolated renal mucormycosis is rare and has not been reported as a complication of Covid-19 disease. Our case developed isolated unilateral emphysematous pyelonephritis and renal mucormycosis after recovery from Covid-19 pneumonia.

Case report

A 46-year-old male patient had developed COVID-19 pneumonia two months back for which he was treated elsewhere with steroids and other supportive medications. Patient was a known case of diabetes and hypertension from last 15 years. One month after his recovery from COVID-19 pneumonia, patient developed persistent fever and left flank pain. He was diagnosed as a case of Class 3B Left Emphysematous Pyelonephritis (Fig. 1). His serum creatinine level was within normal limits. He was initially managed with broad spectrum antibiotics. Left DJ stenting and ultrasound guided drainage of perinephric collection was done with drain kept in situ.
Fig. 1

Computed tomography images showing left emphysematous pyelonephritis.

Computed tomography images showing left emphysematous pyelonephritis. He presented to our hospital two weeks after the placement of DJ stent and drain. He was still having fever episodes and left flank discomfort. His urine output had decreased over the past few days. On evaluation, he looked dehydrated and had facial puffiness. He had left ventricular dysfunction (LVEF – 40%). His blood glucose levels were in the range of 200–350mg/dl, hemoglobin was 10.1mg/dl and his serum creatinine level was 2.4mg/dl. We did not obtain any specific serum fungal culture since were not suspecting any fungal infection at the outset. Routine bacterial blood and urine culture at our hospital did not reveal any fungal growth. After initial stabilization this patient was planned for Left Nephrectomy after discussing the procedure and anticipated complications with the family. Before surgery, patient underwent SLED (sustained low efficiency dialysis) as per nephrologist's advice in view of hyperkalemia and deranged arterial blood gas analysis. Procedure was initially attempted laparoscopically. However, in view of dense inflammation around the kidney, conversion to open surgery was done. Left subcostal incision was made and nephrectomy was completed. Large bowel could be dissected off the kidney. Left kidney was necrotic with multiple pockets of purulent fluid around the kidney. Perirenal fascia appeared thickened. Hilar vessels were encased in inflammatory tissue. Kidney was densely adherent to the posterolateral abdominal wall. A 28Fr abdominal tube drain was placed before the closure of incision. Towards the end of surgery, patient developed hypotension and metabolic acidosis. The blood loss was about 600ml. Despite blood transfusion, vasopressors and therapy for metabolic acidosis, patient could not be extubated. Patient was shifted to ICU and put on ventilatory support. During the post operative period, patient was managed with ventilatory support, antibiotics and other supportive care. In view of oliguria and persistent metabolic acidosis, nephrology consultation was done. Hemodialysis was done as per nephrologist's advice. Histopathology report of the nephrectomy specimen showed mucormycosis. Broad PAS positive hyphae (5–15 μm diameter), irregularly branched with rare septations (Fig. 2) and extensive necrosis (Fig. 3) were seen in the kidney. Liposomal Amphotericin B was started as per the intensivist advice on fourth post operative day. On fifth post operative day, patient developed sudden bradycardia for which resuscitation was done but patient developed cardiopulmonary arrest and could not be reviewed.
Fig. 2

Broad based hyphae seen on microscopy.

Fig. 3

Extensive necrosis seen in kidney.

Broad based hyphae seen on microscopy. Extensive necrosis seen in kidney.

Discussion

Mucormycosis is rare in healthy immunocompetent individuals. However, the use of steroids for the management of Covid −19 disease has increased the risk of opportunistic infections especially in diabetic patients. Several cases of post Covid-19 mucormycosis involving different organs have been reported in literature. In August 2021, Singh AK et al. have presented a systematic review of post covid-19 mucormycosis cases reported in literature. As per the study, 101 cases of mucormycosis in people with COVID-19 were reported which included predominantly male patients (78.9%). Selarka L et al. reported that out of 2567 COVID-19 patients admitted to 3 tertiary centres, 47 (1.8%) were diagnosed with mucormycosis. Most were not COVID-19 vaccinated and had developed moderate-to-severe pneumonia. All patients had received corticosteroids and broad-spectrum antibiotics while most (n = 37, 78.7%) received at least one anti-viral medication. Mean time elapsed from COVID-19 diagnosis to mucormycosis was 12.1 ± 4.6days. Eleven (23.4%) subjects succumbed to their disease, mostly (n = 8, 72.7%) within 7 days of diagnosis. Among the patients who died, 10 (90.9%) had pre-existing diabetes mellitus. Rhinocerebral involvement is the most common form of mucormycosis. Less commonly involved organs include lung, skin or gastrointestinal system. Renal mucormycosis is an extremely rare disease. Bilateral renal mucormycosis is nearly 100% fatal especially in patients with acute kidney injury. A thorough review of literature revealed that till date none of the cases of “post COVID isolated renal mucormycois” has been reported. Choudhary GR et al. has reported a case mucormycosis in a young male following recovery from COVID-19. This patient had simultaneous renal and bowel involvement. This patient was initially managed conservatively. Subsequently he underwent left-sided nephrectomy via the retroperitoneal incision. Intra-operatively, bowel appeared ischemic and congested for which an exploratory laparotomy was performed and gangrenous segment of the bowel beginning from the third part of duodenum till proximal jejunum was resected. This patient developed severe metabolic acidosis, septic shock with anuria and succumbed to his illness after 10 hours. We also had a multi-disciplinary team approach for the management of our patient both in the preoperative and post operative period. Despite our best efforts we could not save the patient. Our patient had poorly controlled diabetes and already had acute kidney injury when he reported to our centre. We believe that an immediate and proactive treatment would have changed the situation. Early nephrectomy should have been done since there was no improvement after placing DJ stent and drain. In fact, the condition of the patient was still deteriorating and he developed acute kidney injury. Early nephrectomy before acute kidney injury developed would have probably changed the outcome. Development of acute kidney injury is a bad prognostic factor in Emphysematous Pyelonephritis and is associated with fatal outcome in Renal Mucormycosis.

Conclusion

Isolated renal mucormycosis can be fatal. High index of suspicion should be there to make the diagnosis. Early detection and aggressive management may have a favourable outcome.
  5 in total

1.  Predictive factors for mortality and need for nephrectomy in patients with emphysematous pyelonephritis.

Authors:  Rakesh Kapoor; Kaliyaperumal Muruganandham; Anil Kumar Gulia; Manish Singla; Saurabh Agrawal; Anil Mandhani; M S Ansari; Aneesh Srivastava
Journal:  BJU Int       Date:  2009-11-20       Impact factor: 5.588

2.  Mucormycosis and acute kidney injury.

Authors:  Krishan L Gupta; Aakriti Gupta
Journal:  J Nephropathol       Date:  2012-10-01

3.  Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India.

Authors:  Awadhesh Kumar Singh; Ritu Singh; Shashank R Joshi; Anoop Misra
Journal:  Diabetes Metab Syndr       Date:  2021-05-21

4.  Mucormycosis and COVID-19: An epidemic within a pandemic in India.

Authors:  Lav Selarka; Suktara Sharma; Dinesh Saini; Sanjay Sharma; Amit Batra; Vishal T Waghmare; Pratibha Dileep; Sanket Patel; Monarch Shah; Tejas Parikh; Prakash Darji; Amit Patel; Gaurav Goswami; Anand Shah; Sandeep Shah; Harsh Lathiya; Moksha Shah; Pranita Sharma; Surabhi Chopra; Ankur Gupta; Neha Jain; Erum Khan; Vijay K Sharma; Arvind K Sharma; Amanda C Y Chan; Jonathan J Y Ong
Journal:  Mycoses       Date:  2021-07-24       Impact factor: 4.931

  5 in total
  1 in total

1.  Clinical presentations, diagnosis, management, and outcomes of renal mucormycosis: An overview of case reports.

Authors:  Mojtaba Didehdar; Zahra Chegini; Amin Khoshbayan; Alireza Moradabadi; Aref Shariati
Journal:  Front Med (Lausanne)       Date:  2022-08-24
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.